AstraZeneca, ENHERTU and Breast Cancer
AstraZeneca's and Daiichi Sankyo's Enhertu wins new approval in US
The Cambridge, England-based and Tokyo-based pharmaceutical companies said the US Food & Drug Administration approved Enhertu for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low, IHC 1+ or IHC 2+/ISH-, or HER2-ultralow, IHC 0, with membrane staining, breast cancer.
AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment
AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo. The Anglo-Swedish pharmaceutical company said Monday that the treatment's approval was based on results from a Phase III trial,
Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.
AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be ...
AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for ...
AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...
Investment analysts at Leerink Partnrs upped their FY2026 EPS estimates for shares of AstraZeneca in a note issued to ...
Our team rates the company as Neutral, with a 5% share price upside potential. Even if we recognize AstraZeneca's market growth drivers, we prefer to remain cautious and wait for a positive drug ...
Astrazeneca Pharma India Ltd share price was down by -0.18% from the previous closing price of ₹7,134.50. Who are peers of Astrazeneca Pharma India Ltd? The peers of Astrazeneca Pharma ...
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
(Alliance News) - AstraZeneca PLC on Thursday announced a USD570 million investment in Canada, creating more than 700 jobs, across all areas of the business.
Hosted on MSN4d
Here's Why Astrazeneca (AZN) is a Strong Growth StockTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback